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1. INTRODUCTION {#jcmm13564-sec-0001}
===============

*Poria cocos* (Figure [1](#jcmm13564-fig-0001){ref-type="fig"}), known as "Fuling" in Chinese, is an edible medicinal mushroom belonging to dry sclerotium of polyporaceae fungi. It has more than 2000 years of medical application history for its remarkable pharmaceutical effect.[1](#jcmm13564-bib-0001){ref-type="ref"} The bioactive components in *Poria cocos* include polysaccharides, triterpenoids, fatty acids, sterols and enzymes. *Poria cocos* polysaccharide (PCP) accounts for 84% by weight among all constituents in the dried sclerotium.[2](#jcmm13564-bib-0002){ref-type="ref"} PCP is also the main bioactive component in *Poria cocos*.

![The fruiting body of Mushroom *Poria cocos*. *Poria cocos* is an edible medicinal fungus known as "Fuling" in Chinese and has been used as a Chinese traditional medicine for more than two thousand years](JCMM-23-4-g001){#jcmm13564-fig-0001}

1.1. The structural composition and properties of PCP {#jcmm13564-sec-0002}
-----------------------------------------------------

PCP is extracted from the sclerotium of *Poria cocos*. Different solvent extraction methods can obtain different polysaccharide fractions, such as WPS (NaOH‐HAc), PAP (1 mol/L NaOH), PCP2 (hot water), PCP1 (0.9% NaCI), PCP3‐I and PCP3‐II (0.5 mol/L NaOH), PCP4‐I and PCP4‐II (88% formic acid).[3](#jcmm13564-bib-0003){ref-type="ref"}, [4](#jcmm13564-bib-0004){ref-type="ref"} Thus, PCP is a mixture of different types of polysaccharides with the molecular weight ranged from 4.1 × 10^4^ to 5 × 10^6^ Da.[5](#jcmm13564-bib-0005){ref-type="ref"} Glucose, fucose, arabinose, xylose, mannose and galactose are detected in PCP. β‐Glucan is the major PCP with β‐(1→3)‐linked glucose backbone and β‐(1→6)‐linked glucose side chains as shown in Figure [2](#jcmm13564-fig-0002){ref-type="fig"}.[3](#jcmm13564-bib-0003){ref-type="ref"}, [6](#jcmm13564-bib-0006){ref-type="ref"} The β‐glucan from *Poria cocos* has poor water solubility but decent anticancer activity.[7](#jcmm13564-bib-0007){ref-type="ref"} Chihara et al removed the β‐(1→6) glucose in the β‐glucan of PCP by periodate oxidation and Smith degradation. The derivative is named "pachymaran," which exhibits better anti‐S‐180 tumour activities.[8](#jcmm13564-bib-0008){ref-type="ref"} Hamuro et al further improved the water solubility issue of pachymaran by chemical carboxymethylation. The carboxymethylated pachymaran (CMP) has enhanced antitumour activity compared to that of pachymaran.[9](#jcmm13564-bib-0009){ref-type="ref"} Subsequently, different chemical modifications, such as sulfation,[10](#jcmm13564-bib-0010){ref-type="ref"} carboxymethylation plus sulfation,[11](#jcmm13564-bib-0011){ref-type="ref"} methylation, hydroxyethylation and hydroxpropylation, have been conducted and different types of modified pachymarans are reported.[12](#jcmm13564-bib-0012){ref-type="ref"} In general, these chemical modified pachymaran derivatives are water‐soluble and show improved bioactivities.

![A schematic diagram of β‐glucan structure in *Poria cocos*. β‐Glucan is the major *Poria cocos* polysaccharide with β‐(1→3)‐linked glucose backbone and β‐(1→6)‐linked glucose side chains. The β‐glucan from *Poria cocos* has poor water solubility but decent anticancer activity](JCMM-23-4-g002){#jcmm13564-fig-0002}

1.2. PCP‐based drug in China {#jcmm13564-sec-0003}
----------------------------

PCP‐based product named "compound polysaccharide oral solution" was developed in the 1970s and was very popular with consumers as health supplement products. In 2006, "Polysaccharidum of *Poria cocos* oral solution" was developed by Hunan Butian pharmaceutical company of China and was granted a Chinese patent (200610163425‐X). The major component (95%) in the patented product is CMP. The water solubility of CMP allows 98% of the components to be absorbed through the human digestive track. In 2015, "Polysaccharidum of *Poria cocos* oral solution" was approved by Chinese Food and Drug Administration with a certified drug number B20050015 for treating multiple types of cancers, hepatitis and other diseases alone or during chemo‐ or radiation therapy for patients with cancer.

1.3. The approach for the literature searching {#jcmm13564-sec-0004}
----------------------------------------------

In this article, a total of 72 publications related to different kinds of *Poria cocos* polysaccharides (PCPs), pachymaran, the derivatives and the biochemical/preclinical/clinical studies up to date were identified through searching PubMed, VIP (Chongqing VIP Chinese Scientific Journals Database), CNKI (China National Knowledge Infrastructure) and Wanfang database. The reported biological and pharmacological activities of PCP are classified based on these publications and shown in Figures [3](#jcmm13564-fig-0003){ref-type="fig"} and [4](#jcmm13564-fig-0004){ref-type="fig"}. The pharmacological and other biological functions and possible molecular mechanisms shown in Figures [3](#jcmm13564-fig-0003){ref-type="fig"} and [4](#jcmm13564-fig-0004){ref-type="fig"} will be the major topics discussed in this article. Moreover, the data that show PCPs can overcome immunosuppression and adverse reactions associated with radiation therapy and chemotherapy[13](#jcmm13564-bib-0013){ref-type="ref"} will also be presented and discussed.

![Pharmacological activities of *Poria cocos* polysaccharides (PCPs). Sixty‐six articles related to pharmacological activities of PCPs are summarized. Thirty‐eight per cent of studies are about antitumour activities of PCPs. Twelve per cent of studies are about antitumour mechanisms. Studies on immunoregulation, antioxidant and toxicity account for 19%, 10% and 7%, respectively. Fourteen per cent of pharmacological activity studies of PCPs are defined as "others" that are further explained in Figure [4](#jcmm13564-fig-0004){ref-type="fig"}](JCMM-23-4-g003){#jcmm13564-fig-0003}

![Other pharmacological activities of PCPs. Antihepatitis effects: 30%; antidiabetic effects: 10%; anti‐epidemic haemorrhagic fever: 10%; anti‐ageing effects: 10%; anti‐inflammatory effects: 10%; and anti‐acute lymphoblastic leukaemia (ALL): 10%](JCMM-23-4-g004){#jcmm13564-fig-0004}

2. PHARMACOLOGICAL ACTIVITIES OF PCP {#jcmm13564-sec-0005}
====================================

2.1. Antitumour {#jcmm13564-sec-0006}
---------------

Parallel to other reported polysaccharides from fungi,[14](#jcmm13564-bib-0014){ref-type="ref"}, [15](#jcmm13564-bib-0015){ref-type="ref"}, [16](#jcmm13564-bib-0016){ref-type="ref"} PCP and its derivatives have more impressive anticancer cell proliferation activities in vivo than in vitro when the same PCP samples are tested both in cancer cell lines and in cancer cell‐injected animal models. The in vitro anticancer cell proliferation effects of PCPs are summarized in Table [1](#jcmm13564-tbl-0001){ref-type="table"}, whereas the in vivo antitumour growth effects of PCPs are summarized in Table [2](#jcmm13564-tbl-0002){ref-type="table"} from 15 independent studies.[17](#jcmm13564-bib-0017){ref-type="ref"}, [18](#jcmm13564-bib-0018){ref-type="ref"}, [19](#jcmm13564-bib-0019){ref-type="ref"}, [20](#jcmm13564-bib-0020){ref-type="ref"}, [21](#jcmm13564-bib-0021){ref-type="ref"}, [22](#jcmm13564-bib-0022){ref-type="ref"}, [23](#jcmm13564-bib-0023){ref-type="ref"}, [24](#jcmm13564-bib-0024){ref-type="ref"}, [25](#jcmm13564-bib-0025){ref-type="ref"}, [26](#jcmm13564-bib-0026){ref-type="ref"}, [27](#jcmm13564-bib-0027){ref-type="ref"}, [28](#jcmm13564-bib-0028){ref-type="ref"}, [29](#jcmm13564-bib-0029){ref-type="ref"}, [30](#jcmm13564-bib-0030){ref-type="ref"}

###### 

Abbreviation list

  Abbreviation   Full name                                                                             Abbreviation   Full name
  -------------- ------------------------------------------------------------------------------------- -------------- -------------------------------------------------
  ALL            Acute lymphoblastic leukaemia                                                         LCT            Lymphocytes transformation
  ACV            Acyclovir                                                                             LLC            Lewis lung carcinoma
  Bcl‐2          B‐cell lymphoma‐2                                                                     ‐L             Low dosage
  Bcap‐37        Breast carcinoma cells                                                                ‐M             Medium dosage
  Bax            Bcl‐2 Assaciated X protein                                                            MPCP           Methylated *poria cocos* polysaccharide
  BHT            Butylated hydroxytoluene                                                              MAO            Monoamine oxidase
  CMP            Carboxymethylated pachymaran                                                          MDA            Malondialdehyde
  CTX            Cyclophosphamide                                                                      NS             Normal saline
  CA             Cortisone acetate                                                                     NK             Natural killer cell
  CP             Hericium erinaceus polysaccharide+Lentinan+Pachymaran                                 OH             Hydroxyl free radical
  CPABM          Agaricus blazei murill polysaccharide+Lentinan+CMP                                    PCP            *Poria cocos* polysaccharide
  DAG            Dianhydrogalactitol                                                                   PCP1           Polysaccharide extracted using 0.9% NaCI
  DXM            Dexamethasone                                                                         PCP2           Polysaccharide extracted using hot water
  DPPH           1,1‐Diphenyl‐2‐picrylhydrazyl radical 2,2‐Diphenyl‐1‐(2,4,6‐trinitrophenyl)hydrazyl   PCP3           Polysaccharide extracted using 0.5 mol/L NaOH
  EC50           50% effective concentration                                                           PCP4           Polysaccharide extracted using 88% formic acid
  Ea             Active erythrocyte rosettle test                                                      PTPP           Phosphorylation of protein tyrosine phosphatase
  Et             Total erythrocyte rosettle test                                                       PT             Pachymaran and triterpens
  EAC            Ehrlich ascites carcinoma cells                                                       PS             Pachymaran (Sulphated)
  FP             Ferulic acid pachymaran                                                               Pt             Cisplatin
  HBsAg          Hepatitis B surface antigen                                                           PAP            Acidic pachymaran
  HBeAg          Hepatitis Be Antigen                                                                  SGC‐7901       Gastric carcinoma cells
  HE‐PCP         Hydroxyethylated *poria cocos* polysaccharide                                         SOD            Superoxide dismutase
  HP‐PCP         Hydroxypropylated *poria cocos* polysaccharide                                        SGPT           Serum glutamic pyruvic transaminase
  H~22~          H~22~ hepatoma                                                                        TNF            Tumour necrosis factor
  HPBL           Human peripheral blood lymphocyte                                                     TPK            Tyrosine protein kinase
  ‐H             High dosage                                                                           U~‐14~         U‐14 ascitic fluid tumour cells
  IC50           Half maximal inhibitory concentration                                                 Vc             Vitamin C
  IFN‐γ          Interferon‐γ                                                                          WPS            Polysaccharide extracted using NaOH‐HAc
  KSC            Kappa‐selenocarrageenan                                                               5‐Fu           5‐fluoro‐2,4(1H,3H) pyrimidinedione
  LH             Levamisole hydrochloride                                                                             
  Lewis          Lung carcinoma cell                                                                                  

John Wiley & Sons, Ltd

###### 

Inhibition rates of PCPs on different cancer cells

  Cell types         Groups            Cancer inhibition rates (%)   *P*‐value   References
  ------------------ ----------------- ----------------------------- ----------- -------------------------------------------
  SGC‐7901 (human)   Distilled water   0                                         [17](#jcmm13564-bib-0017){ref-type="ref"}
  5‐Fu‐L             34.98                                                       
  5‐Fu‐M             69.92                                                       
  5‐Fu‐H             85.05                                                       
  PCP2‐L             60.09                                                       
  PCP2‐M             90.04                                                       
  PCP2‐H             96.10                                                       
  Bcap‐37 (human)    5‐Fu‐L            35.41                                     
  5‐Fu‐M             61.04                                                       
  5‐Fu‐L             88.72                                                       
  PCP2‐L             42.48                                                       
  PCP2‐M             85.09                                                       
  PCP2‐H             88.54                                                       
  HepG2 (human)      PAP1              14.22 ± 1.06                              [4](#jcmm13564-bib-0004){ref-type="ref"}
  PAP2               16.65 ± 3.01                                                
  PAP3               6.94 ± 2.08                                                 
  PAP4               15.98 ± 4.16                                                
  PAP5               16.71 ± 1.72                                                
  PAP6               16.02 ± 2.65                                                
  PAP7               59.76 ± 5.47      *P *\< .05                                
  PAP8               23.45 ± 1.31      *P *\< .05                                
  PAP9               78.67 ± 1.68      *P* \< .01                                
  PAP10              82.92 ± 2.8       *P* \< .01                                
  K562 (human)       NS                0                                         [30](#jcmm13564-bib-0030){ref-type="ref"}
  PS‐L               16.95 ± 5.16                                                
  PS‐M               27.80 ± 3.57                                                
  PS‐H               52.95 ± 1.2                                                 

John Wiley & Sons, Ltd

PCPs possess decent anticancer cell proliferation effect in vitro, which is measured in cell cultures where different tumour cell lines derived from human or mouse tumours have been tested, such as SGC‐7901 (human), Bcap‐37 (human), HepG2 (human) and K562 (human) cells (Table [2](#jcmm13564-tbl-0002){ref-type="table"}). For example, the inhibition rate for SGC‐7901 cells is 96% compared to that of 88% for Bcap‐37 cells.[17](#jcmm13564-bib-0017){ref-type="ref"} As shown in Table [2](#jcmm13564-tbl-0002){ref-type="table"}, the inhibition rates of PCP or its derivatives on the proliferation of cancer cells are largely concentration‐dependent, which resembles the control drug 5‐fluoro‐2,4(1H,3H) pyrimidinedione or 5‐Fu.

In contrast, in cancer cell‐injected animal models (Table [3](#jcmm13564-tbl-0003){ref-type="table"}), the inhibition rates of PCP or its derivatives on tumour growth are only partially concentration‐dependent in that within a certain range, the higher the concentrations, the higher the inhibition rates are. But beyond the range, the inhibition rates will drop. For example, the experiment conducted by Cheng et al[18](#jcmm13564-bib-0018){ref-type="ref"} showed that the inhibition rates of cancer cell growth are 0, 69%, 87%, 92% and 89%, respectively, with increasing CMP concentrations.

###### 

Tumour inhibition rates of PCPs in animal models

  Models                        Administration route          Cell types        Groups            Tumour weight (g)   *P*‐value   Tumour inhibition rates (%)   *P*‐value   References
  ----------------------------- ----------------------------- ----------------- ----------------- ------------------- ----------- ----------------------------- ----------- -------------------------------------------
  ICR mice                      Intragastric administration   S~‐180~(mouse)    Distilled water   2.742 ± 0.378                   0                                         [20](#jcmm13564-bib-0020){ref-type="ref"}
  5‐Fu                          1.341 ± 0.135                 *P* \< .001       45.73                                                                                       
  CMP‐L                         1.972 ± 0.399                 *P* \< .05        2.23                                                                                        
  CMP‐H                         1.675 ± 0.412                 *P* \< .01        32.22                                                                                       
  5‐Fu+CMP‐L                    1.413 ± 0.394                 *P* \< .001       42.83                                                                                       
  5‐Fu+CMP‐H                    1.283 ± 0.483                 *P* \< .001       48.11                                                                                       
  ICR/JCL mice                  Intraperitoneal injection     U~‐14~ (mouse)    NS                1.385 ± 0.101                   0                                         [18](#jcmm13564-bib-0018){ref-type="ref"}
  CMP (30 mg/kg)                0.433 ± 0.105                 *P* \< .01        68.7                                                                                        
  CMP (120 mg/kg()              0.182 ± 0.121                 *P* \< .01        86.9                                                                                        
  CMP (180 mg/kg)               0.108 ± 0.053                 *P* \< .01        92.2                                                                                        
  CMP (360 mg/kg)               0.151 ± 0.113                 *P* \< .01        89.1                                                                                        
  Kunming mice                  Intraperitoneal injection     S~‐180~ (mouse)   NS                1.23 ± 0.11                     0                                         [21](#jcmm13564-bib-0021){ref-type="ref"}
  CTX                           0.49 ± 0.07                   *P* \< .01        60.21                                                                                       
  WPS‐L                         0.99 ± 0.10                                     19.53                                                                                       
  WPS‐M                         0.89 ± 0.12                   *P* \< .01        28.01                                                                                       
  WPS‐H                         0.72 ± 0.08                   *P* \< .01        43.94                                                                                       
  WPS1‐L                        0.98 ± 0.13                                     2.32                                                                                        
  WPS1‐M                        0.96 ± 0.06                   *P* \< .1         22.45                                                                                       
  WPS1‐H                        0.70 ± 0.07                   *P* \< .01        41.57                                                                                       
  WPS2‐L                        1.09 ± 0.08                                     11.45                                                                                       
  WPS2‐M                        0.98 ± 0.10                   *P* \< .1         2.32                                                                                        
  WPS2‐H                        0.74 ± 0.04                   *P* \< .01        39.81                                                                                       
  Kunming mice                  Intragastric administration   S~‐180~ (mouse)   NS                0.753 ± 0.191                   0                                         [22](#jcmm13564-bib-0022){ref-type="ref"}
  CTX                           0.155 ± 0.091                 *P* \< .05        79                                                                                          
  PCP‐L                         0.437 ± 0.117                 *P* \< .05        42                                                                                          
  PCP‐M                         0.482 ± 0.105                 *P* \< .05        36                                                                                          
  PCP‐H                         0.527 ± 0.152                 *P* \< .05        30                                                                                          
  BALB/c mice                   Intraperitoneal injection     S~‐180~ (mouse)   PBS               1.61 ± 0.32                     0                                         [19](#jcmm13564-bib-0019){ref-type="ref"}
  5‐Fu                          0.76 ± 0.16                                     52.76             *P* \< .01                                                                
  PCP3‐II‐L                     1.56 ± 0.42                                     2.46                                                                                        
  PCP3‐II‐H                     1.57 ± 0.66                                     3.02                                                                                        
  PS‐L                          1.39 ± 0.27                                     13.88                                                                                       
  PS‐H                          1.21 ± 0.41                                     34.63             *P* \< .05                                                                
  CMP‐L                         1.23 ± 0.48                                     23.45             *P* \< .05                                                                
  CMP‐H                         1.04 ± 0.20                                     35.27             *P* \< .01                                                                
  MPCP3‐II‐L                    1.34 ± 0.46                                     16.65                                                                                       
  MPCP3‐II‐H                    1.22 ± 0.38                                     24.48             *P* \< .05                                                                
  HE‐PCP3‐II‐L                  1.63 ± 0.36                                                                                                                                 
  HE‐PCP3‐II‐H                  1.29 ± 0.29                                     20.20                                                                                       
  HP‐PCP3‐II‐L                  1.45 ± 0.27                                     10.00                                                                                       
  HP‐PCP3‐II‐H                  1.37 ± 0.48                                     14.88                                                                                       
  PBS                           1.40 ± 0.32                                     0                                                                                           
  5‐Fu                          0.76 ± 0.27                                     46.0              *P* \< .01                                                                
                                                                                PS‐2‐L            1.09 ± 0.26                     22.32                                     
  PS‐2‐H                        0.90 ± 0.36                                     35.71             *P* \< .05                                                                
  PS‐4‐L                        0.89 ± 0.18                                     36.51             *P* \< .05                                                                
  PS‐4‐H                        0.97 ± 0.36                                     30.95                                                                                       
  PS‐5‐L                        0.91 ± 0.34                                     34.92             *P* \< .05                                                                
  PS‐5‐H                        0.86 ± 0.26                                     38.39             *P* \< .05                                                                
  PS‐6‐L                        1.14 ± 0.12                                     18.25                                                                                       
  PS‐6‐H                        1.16 ± 0.39                                     17.35                                                                                       
  PS‐9‐L                        0.92 ± 0.29                                     33.93             *P* \< .05                                                                
  PS‐9‐H                        0.93 ± 0.38                                     33.33             *P* \< .05                                                                
  BalB/c mice                   Intraperitoneal injection     S~‐180~ (mouse)   PBS               1.407 ± 0.32                    0                                         [23](#jcmm13564-bib-0023){ref-type="ref"}
  5‐Fu                          0.867 ± 0.26                                    46                *P* \< .01                                                                
  PS                            0.767 ± 0.27                                    38.39             *P* \< .05                                                                
  ICR/JCL mice                  Intragastric administration   S~‐180~ (mouse)   NS                1.989 ± 0.594                   0                                         [24](#jcmm13564-bib-0024){ref-type="ref"}
  5‐Fu                          0.363 ± 0.286                 *P* \< .01        81.7                                                                                        
  CMP‐L                         1.282 ± 0.166                 *P* \< .05        35.5                                                                                        
  CMP‐M                         1.159 ± 0.126                 *P* \< .05        41.6                                                                                        
  CMP‐H                         0.963 ± 0.364                 *P* \< .05        51.6                                                                                        
  Intravenous injection         S~‐180~ (mouse)               NS                3.425 ± 0.958                         0                                                     
  5‐Fu                          0.323 ± 0.261                 *P* \< .01        90.6                                                                                        
  CMP‐L                         2.106 ± 1.037                 *P* \< .05        38.5                                                                                        
  CMP‐M                         2.294 ± 1.037                 *P* \< .05        32                                                                                          
  CMP‐H                         2.049 ± 0.752                 *P* \< .05        40.2                                                                                        
  Intragastric administration   H~22~ (mouse)                 NS                1.721 ± 0.571                         0                                                     
  5‐Fu                          0.269 ± 0.230                 *P* \< .01        84.65                                                                                       
  CMP‐L                         0.760 ± 0.470                 *P* \< .05        55.58                                                                                       
  CMP‐M                         1.044 ± 0.438                 *P* \< .05        39.03                                                                                       
  CMP‐H                         0.644 ± 0.438                 *P* \< .01        62.24                                                                                       
  ICR/JCL mice                  Intraperitoneal injection     U~‐14~ (mouse)    NS                1.225 ± 0.122                   0                                         [25](#jcmm13564-bib-0025){ref-type="ref"}
  CMP (25 mg/kg)                0.253 ± 0.11                  *P* \< .01        79.4                                                                                        
  CMP (50 mg/kg)                0.26 ± 0.137                  *P* \< .01        78.8                                                                                        
  CMP (100 mg/kg)               0.089 ± 0.003                 *P* \< .01        92.7                                                                                        
  CMP (500 mg/kg)               0.30 ± 0.095                  *P* \< .01        75.5                                                                                        
  Intravenous injection         S~‐180~ (mouse)               NS                3.431 ± 1.136                         0                                                     
  CMP‐L                         2.237 ± 0.977                 *P* \< .05        34.8                                                                                        
  CMP‐M                         2.141 ± 0.969                 *P* \< .05        37.6                                                                                        
  CMP‐H                         1.339 ± 0.683                 *P* \< .01        61                                                                                          
  Intravenous injection         H~22~ (mouse)                 NS                2.167 ± 0.812                         0                                                     
  CMP‐L                         1.732 ± 0.988                                   20.1                                                                                        
  CMP‐M                         1.372 ± 0.673                 *P* \< .05        36.7                                                                                        
  CMP‐H                         1.485 ± 0.931                 *P* \< .05        31.5                                                                                        
  NIH mice                      Intragastric administration   S~‐180~ (mouse)   NS                1.34 ± 0.32                     0                                         [26](#jcmm13564-bib-0026){ref-type="ref"}
  5‐Fu                          0.54 ± 0.43                   *P* \< .001       59.7              *P* \< .01                                                                
  CMP‐L                         0.48 ± 0.34                   *P* \< .001       64.18             *P* \< .01                                                                
  CMP‐M                         0.70 ± 0.36                   *P* \< .001       47.76             *P* \< .05                                                                
  CMP‐H                         0.51 ± 0.53                   *P* \< .001       61.94             *P* \< .01                                                                
  S~‐180~ (mouse)               NS                            1.30 ± 0.22                         0                                                                         
  5‐Fu                          0.67 ± 0.14                   *P* \< .001       48.46             *P* \< .05                                                                
  CMP‐L                         0.54 ± 0.12                   *P* \< .001       58.46             *P* \< .01                                                                
  CMP‐M                         0.78 ± 0.14                   *P* \< .001       40.00             *P* \< .05                                                                
  CMP‐H                         0.74 ± 0.16                   *P* \< .001       43.08             *P* \< .05                                                                
  EAC(mouse)                    NS                            1.06 ± 0.16                         0                                                                         
  5‐Fu                          0.45 ± 0.16                   *P* \< .001       57.55             *P* \< .01                                                                
  CMP‐L                         0.43 ± 0.18                   *P* \< .001       59.43             *P* \< .001                                                               
  CMP‐H                         0.54 ± 0.21                   *P* \< .001       49.06             *P* \< .05                                                                
  EAC(mouse)                    NS                            1.02 ± 0.15                         0                                                                         
  5‐Fu                          0.41 ± 0.19                   *P* \< .001       59.80             *P* \< .01                                                                
  CMP‐L                         0.51 ± 0.28                   *P* \< .001       50.00             *P* \< .01                                                                
  CMP‐H                         0.62 ± 0.25                   *P* \< .001       39.22             *P* \< .05                                                                
  ICR/ICJ mice                  Intragastric administration   S~‐180~ (mouse)   NS                2.49 ± 0.42                     0                                         [28](#jcmm13564-bib-0028){ref-type="ref"}
                                PCP‐L                         1.29 ± 0.28       *P* \< .01        48.1                                                                      
                                PCP‐M                         1.46 ± 0.46       *P* \< .01        41.37                                                                     
                                PCP‐H                         2.25 ± 0.67                         .96                                                                       
  CFW mice                      Intraperitoneal injection     S~‐180~ (mouse)   NS                5.1 ± 0.9                       0                                         [29](#jcmm13564-bib-0029){ref-type="ref"}
  PCP‐H                         2.9 ± 1.0                                       43.1              *P* \< .01                                                                
  PCP‐M                         3.1 ± 1.1                                       39.2              *P* \< .01                                                                
  PCP‐L                         3.2 ± 1.7                                       37.3              *P* \< .01                                                                
  Rats                          Intraperitoneal injection     S~‐180~ (mouse)   NS                10.2 ± 2.6                      0                                         [27](#jcmm13564-bib-0027){ref-type="ref"}
  PCP                           5.77 ± 2.7                                      39.9              *P* \< .01                                                                
  PS                            6.10 ± 3.0                                      43.2              *P* \< .01                                                                

John Wiley & Sons, Ltd

The inhibition of tumour growth in vivo is measured either by the reduced tumour weight or by ultrasound compared to controls in different animal models and presented as tumour inhibition rates (%). The controls include blank and positive controls where the chemotherapeutic drug, such as 5‐fluoro‐2, 4 (1H, 3H) pyrimidinedione (5‐Fu), is used. PCPs have potent antitumour activities in different animal tumour models when compared to blank or 5‐Fu controls (Table [3](#jcmm13564-tbl-0003){ref-type="table"}). When PCP is modified with different chemical groups, such as carboxymethyl, sulphate, methyl, hydroxypropyl and hydroxyethyl, the derivatives exhibit better inhibition rates. For example, Wang et al extracted six polysaccharides from the fresh sclerotium of *Poria cocos* using different solvents sequentially, including PCP1 (0.9% NaCl), PCP2 (hot water), PCP3‐I and PCP3‐II (0.5 mol/L NaOH), PCP4‐I and PCP4‐II (88% formic acid). They then modified PCP3‐II chemically and obtained five different PCP3‐II derivatives.[3](#jcmm13564-bib-0003){ref-type="ref"} They showed[19](#jcmm13564-bib-0019){ref-type="ref"} that all the derivatives inhibit tumour growth better than PCP3‐II with the inhibiting rates increased by 36% and 35% for sulphated and carboxymethyled derivatives, respectively, and by 24%, 15% and 20% for methylated, hydroxypropylated and hydroxyethylated derivatives, respectively. They further demonstrated that the increased degree of chemical modifications and the increased molecular weight in the derivatives correlate with better inhibiting rates in vivo.

Furthermore, the curing effects can be further enhanced when PCPs are combined with chemotherapeutic drugs in different animal models. In addition, the combined therapy also reduces the adverse effects associated with chemotherapeutic drugs (Table [4](#jcmm13564-tbl-0004){ref-type="table"}). For example, Liu et al[31](#jcmm13564-bib-0031){ref-type="ref"} Tang et al[32](#jcmm13564-bib-0032){ref-type="ref"} and Chen et al[29](#jcmm13564-bib-0029){ref-type="ref"} reported that PCPs exhibit better tumour inhibition rates when it is used with other chemotherapeutic drugs. For instance, inhibition rates were 46% when PCP is used with 5‐Fu compared with the inhibition rates of 41% when 5‐Fu is used alone.[29](#jcmm13564-bib-0029){ref-type="ref"}

###### 

Tumour inhibition rates of PCPs ± chemotherapy on mice

  Models                 Administration routs          Cell types        Groups          Tumour weight(g)   *P*‐value   Tumour inhibition rates (%)   *P*‐value   References
  ---------------------- ----------------------------- ----------------- --------------- ------------------ ----------- ----------------------------- ----------- -------------------------------------------
  Kunming mice           Intragastric administration   S~‐180~ (mouse)   NS              3.01 ± 0.38                    0                                         [31](#jcmm13564-bib-0031){ref-type="ref"}
  CTX                    0.84 ± 0.21                   *P* \< .01        72.1                                                                                     
  CPABM‐L                2.10 ± 0.28                   *P* \< .01        30.2                                                                                     
  CPABM‐M                1.43 ± 0.24                   *P* \< .01        52.5                                                                                     
  CPABM‐H                2.69 ± 0.32                                     10.6                                                                                     
  CPABM+CTX‐L            0.52 ± 0.16                   *P* \< .01        82.7                                                                                     
  CPABM+CTX‐M            0.50 ± 0.19                   *P* \< .01        83.4                                                                                     
  CPABM+CTX‐H            1.03 ± 0.31                   *P* \< .01        65.8                                                                                     
  Kunming and NIH mice   Intragastric administration   S~‐180~ (mouse)   NS              1.89 ± 0.24                    0                                         [32](#jcmm13564-bib-0032){ref-type="ref"}
  CP‐L                   1.18 ± 0.29                   *P* \< .05        37.73 ± 13.11                                                                            
  CP‐M                   1.03 ± 0.36                   *P* \< .05        44.74 ± 19.33                                                                            
  CP‐H                   0.98 ± 0.26                   *P* \< .05        48.34 ± 13.08                                                                            
  CFW mice               Intraperitoneal injection     S~‐180~ (mouse)   NS              1.4 ± 0.6                      0                                         [29](#jcmm13564-bib-0029){ref-type="ref"}
  5‐Fu                   0.7 ± 0.2                                       50              *P* \< .05                                                               
  CTX                    1.1 ± 0.4                                       21.4                                                                                     
  DAG                    0.9 ± 0.4                                       35.7            *P* \< .05                                                               
  PCP                    1.0 ± 0.4                                       28.6                                                                                     
  PCP+5‐Fu               0.9 ± 0.3                                       35.7            *P* \< .05                                                               
  PCP+CTX                0.8 ± 0.3                                       42.9            *P* \< .05                                                               
  PCP+DAG                0.8 ± 0.3                                       42.9            *P* \< .05                                                               
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2.2. Antitumour mechanisms {#jcmm13564-sec-0007}
--------------------------

PCPs exert their antitumour activity via assisting the host to overcome adverse biological stresses, to increase immunity against the tumours and to promote the apoptosis of tumour cells directly. The possible mechanisms reported so far are summarized in Table [5](#jcmm13564-tbl-0005){ref-type="table"}A‐D and Figure [5](#jcmm13564-fig-0005){ref-type="fig"}, [33](#jcmm13564-bib-0033){ref-type="ref"}, [34](#jcmm13564-bib-0034){ref-type="ref"}, [35](#jcmm13564-bib-0035){ref-type="ref"}, [36](#jcmm13564-bib-0036){ref-type="ref"}, [37](#jcmm13564-bib-0037){ref-type="ref"}, [38](#jcmm13564-bib-0038){ref-type="ref"} and discussed below.

###### 

\(A\) Antitumour mechanisms of PCP: impact on expression rates of Fas, Bcl‐2 and Bax, the ratio of lymphocyte, killing activity of NK cell, IFN‐γ, TNF, phagocytic ability and IL‐2 (B) Antitumour mechanisms of PCP: impact on IFN‐γ, TNF, phagocytic ability, IL‐6, TPK in cytoplasm and cytomembrane, PTPP in cytoplasm and cytomembrane (C) Antitumour mechanisms of PCP: impact on phagocytic ability, thymus index, spleen index and IFN‐r (D) Antitumour mechanisms of PCP: impact on haemolysin, IL‐4, IgA in serum, IgG in serum and IgM in serum

  Models        Administration routs          Cell types   Groups   Expression rates (%)   The ratio of lymphocyte (%)   Killing activity of NK cell (%)   IFN‐γ (IU/mL)         TNF (ug/mL)   Phagocytic ability (%)   IL‐2 (IU)        References      
  ------------- ----------------------------- ------------ -------- ---------------------- ----------------------------- --------------------------------- --------------------- ------------- ------------------------ ---------------- ------------ -- -------------------------------------------
  \(A\)                                                                                                                                                                                                                                                  
  BALB/c mice   Intraperitoneal injection     S~‐180~      PBS      4.12                   47.96                         2.45                                                                                                                            [33](#jcmm13564-bib-0033){ref-type="ref"}
  PS            64.99                         17.97        48.05                                                                                                                                                                                         
  BALB/c mice   Intraperitoneal injection     H~22~        NS                              46.52                         45.38                                                                                          0.08 (TNF‐α)                     [34](#jcmm13564-bib-0034){ref-type="ref"}
  CMP‐L                                       52.55        52.64                                                                                           0.128 (TNF‐α)                                                                                 
  CMP‐M                                       62.39        61.88                                                                                           0.134 (TNF‐α)                                                                                 
  CMP‐H                                       56.15        54.45                                                                                           0.135 (TNF‐α)                                                                                 
  NIH mice      Intragastric administration   EAC          NS                                                                                                                    12.01                                  8.05 × 10^\^5^                   [26](#jcmm13564-bib-0026){ref-type="ref"}
  5‐Fu                                                                                     16.01                                                           12.28 **×** 10^\^5^                                                                           
  CMP‐L                                                                                    14.82                                                           8.5 × 10^\^5^                                                                                 
  CMP‐H                                                                                    15.56                                                           9.69 × 10^\^5^                                                                                
  NS                                                                                                                                                                                           24.92                                                     
  NS+CTX                                                                                                                                                                                       13.01                                                     
  CMP‐L+CTX                                                                                                                                                                                    19.52                                                     
  CMP‐H+CTX                                                                                                                                                                                    21.67                                                     
  CFW mice      Intraperitoneal injection     S~‐180~      NS                                                                                                                                                                            9.3             [29](#jcmm13564-bib-0029){ref-type="ref"}
  PCP‐L                                                                                                                                                                          21.9                                                                    
  PCP‐H                                                                                                                                                                          24.5                                                                    

  Models         Administration routs     Cell types   Groups       IFN‐γ (IU/mL)   TNF (ug/mL)   Phagocytic ability (%)   IL‐6 (IU)   TPK in cytoplasm (min^−1^× μn^−1^)   TPK in cytomembrane (min^−1^ × μg^−1^)   PTPP in cytoplasm (min^−1^ × μg^−1^)   PTPP in cytomembrane (min^−1^ × μg^−1^)   References
  -------------- ------------------------ ------------ ------------ --------------- ------------- ------------------------ ----------- ------------------------------------ ---------------------------------------- -------------------------------------- ----------------------------------------- -------------------------------------------
  \(B\)                                                                                                                                                                                                                                                                                               
  ICR/ICJ mice   Subcutaneous injection   LLC          NS                                         24.44                                                                                                                                                                                               [36](#jcmm13564-bib-0036){ref-type="ref"}
  CMP                                                  59.26                                                                                                                                                                                                                                          
  S~‐180~        NS                                                 26.88                                                                                                                                                                                                                             
  CMP                                                  45.92                                                                                                                                                                                                                                          
  Cancer cells                            HPBL         NS                           5.0                                    1299.3                                                                                                                                                                     [35](#jcmm13564-bib-0035){ref-type="ref"}
                 CMP‐L                                 22.2                         1356.3                                                                                                                                                                                                            
                 CMP‐M                                 41.9                         1837.4                                                                                                                                                                                                            
                 CMP‐H                                 48.3                         1880.6                                                                                                                                                                                                            
  Cancer cells                            HL‐60        Control                                                                         105.1                                197.8                                    1.93                                   0.97                                      [37](#jcmm13564-bib-0037){ref-type="ref"}
                 PCP                                                                              62.5                     158.1       6.08                                 3.14                                                                                                                      
  Cancer cells                            HPBL         Control      3400            315 (U/mL)                             4232                                                                                                                                                                       [38](#jcmm13564-bib-0038){ref-type="ref"}
                 CMP                      6216         450 (U/mL)                   6478                                                                                                                                                                                                              

  Models         Administration routs          Groups   Phagocytic ability (%)   Thymus index   Spleen index   IFN‐γ (pg/mL)   References
  -------------- ----------------------------- -------- ------------------------ -------------- -------------- --------------- -------------------------------------------
  \(C\)                                                                                                                        
  Kunming mice   Intragastric administration   NS       45.5                     2.19           2.10                           [42](#jcmm13564-bib-0042){ref-type="ref"}
  LH             67.83                         2.73     2,92                                                                   
  PT‐L           58.83                         2.72     2.85                                                                   
  PT‐M           70.17                         2.74     2.93                                                                   
  PT‐H           69.67                         2.73     2.91                                                                   
  C57BL/6 mice   Intravenous injection         NS                                               1.15                           [44](#jcmm13564-bib-0044){ref-type="ref"}
  Pt                                                    0.42                                                                   
  PCP‐L                                                 1.1                                                                    
  PCP‐H                                                 1.41                                                                   
  Kunming mice   Intraperitoneal injection     NS                                3.09                                          [45](#jcmm13564-bib-0045){ref-type="ref"}
  DXM                                          1.11                                                                            
  PS+DXM                                       1.89                                                                            
  PS                                           2.84                                                                            
  BALB/c mice    Intraperitoneal injection     NS                                                              77.00           [43](#jcmm13564-bib-0043){ref-type="ref"}
  CMP                                                                            248.33                                        
  NIH mice       Intragastric administration   NS       58.36                    47.14          73.00                          [26](#jcmm13564-bib-0026){ref-type="ref"}
  CTX            37.64                         23.17    42.34                                                                  
  CMP‐L          48.36                         27.91    43.55                                                                  
  CMP‐M          51.09                         30.28    54.88                                                                  
  CMP‐H          55.18                         36.73    58.69                                                                  
  ICR/ICJ mice   Subcutaneous injection        NS       39.65                                                                  [36](#jcmm13564-bib-0036){ref-type="ref"}
  CMP            59.26                                                                                                         
  NS             30.39                                                                                                         
  CA             18.86                                                                                                         
  CA+CMP         34.81                                                                                                         
  CMP            50.48                                                                                                         
  NS                                           24.75    56.84                                                                  
  CTX                                          22.25    45.7                                                                   
  CTX+CMP                                      19.08    45.57                                                                  
  CMP                                          33.82    69.87                                                                  

  Models         Administration routs          Groups   Haemolysin (OD~450~)   IL‐4 (pg/mL)   IgA in serum (μg/mL)   IgG in serum (ng/mL)   IgM in serum (ng/mL)   References
  -------------- ----------------------------- -------- ---------------------- -------------- ---------------------- ---------------------- ---------------------- -------------------------------------------
  \(D\)                                                                                                                                                            
  Kunming mice   Intragastric administration   NS                                             61.45                  286.64                 2.23                   [46](#jcmm13564-bib-0046){ref-type="ref"}
  LH                                                    97.32                  378.46         2.81                                                                 
  PCP (60%)‐L                                           103.67                 376.19         2.78                                                                 
  PCP (60%)‐M                                           122.38                 570.30         3.53                                                                 
  PCP (60%)‐H                                           139.65                 706.79         4.58                                                                 
  Kunming mice   Intragastric administration   NS       0.4081                 67.8                                  852.1                  655.4                  [47](#jcmm13564-bib-0047){ref-type="ref"}
  CTX            0.1891                        43.8                            585.5          302.4                                                                
  CTX+PCP‐L      0.2630                        56.6                            773.3          465.2                                                                
  CTX+PCP‐H      0.2949                        64.1                            822.5          504.1                                                                
  PCP            0.4967                        84.1                            1071.2         655.4                                                                
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![Possible antitumour mechanisms of PCPs. PCPs exert their antitumour activity via assisting the host to overcome adverse biological stresses, to assist the host to enhance the lethality of macrophages, T cells, B cells and NK cells by releasing cytokines to increase immunity, and to promote the apoptosis of tumour cells directly by up‐regulating the expression of apoptosis‐related genes](JCMM-23-4-g005){#jcmm13564-fig-0005}

### 2.2.1. Enhancing the innate immunity through activating the immune cells {#jcmm13564-sec-0008}

Polysaccharides could activate effector immune cells, such as macrophages, lymphocytes and natural killer (NK) cells to activate the innate immune system to exert antitumour activity by accelerating the host\'s defence mechanisms.[33](#jcmm13564-bib-0033){ref-type="ref"} It is reported that the ratio of lymphocytes could increase to 62% in the treatment group compared with control group (47%)[34](#jcmm13564-bib-0034){ref-type="ref"} and phagocytic ability of macrophages could reach 59% compared with control group of 27%.[36](#jcmm13564-bib-0036){ref-type="ref"}

### 2.2.2. Increasing cytokine levels {#jcmm13564-sec-0009}

TNF (tumour necrosis factor) secreted by macrophages and lymphocytes is used as a drug for tumour biotherapy. IL‐6 (interleukin‐6) secreted by T lymphocytes and fibroblasts improves the killing ability of NK cells. Miu et al and Chen et al found that carboxymethyl pachymaran could improve the levels of IFN‐γ, IL‐2, TNF and IL‐6.[35](#jcmm13564-bib-0035){ref-type="ref"}, [38](#jcmm13564-bib-0038){ref-type="ref"}

### 2.2.3. Stimulating the expression of apoptosis‐related genes {#jcmm13564-sec-0010}

Bcl‐2 and Bax are members of the Bcl‐2 family, which are important for the regulation of apoptosis. The Bax/Bcl‐2 ratio determines the survival of cells. Meng reported that sulphated pachymaran could enhance the expression of apoptosis‐related genes Fas and Bax and reduce the expression of Bcl‐2 gene. The increased Bax/Bcl‐2 ratio is responsible for the apoptosis of S180 tumour cells in the mouse model.[33](#jcmm13564-bib-0033){ref-type="ref"} Zhang et al showed that WPS could inhibit the growth of human breast carcinoma MCF‐7 cells by inducing G1 arrest of the cell cycle and by elevating the Bax/Bcl‐2 ratio.[39](#jcmm13564-bib-0039){ref-type="ref"}

### 2.2.4. Regulating the activities of TPK and PTPP in cancer cells {#jcmm13564-sec-0011}

TPK (tyrosine protein kinase) and PTPP (phosphotyrosine protein phosphatase) are two important enzymes controlling the growth, proliferation and differentiation of cells. Several studies reported that the activities of TPK and PTPP have changed significantly when the cells become cancerous, but PCP normalizes the activities of TPK and PTPP in cancer cells and slowdowns cancer cell growth.[37](#jcmm13564-bib-0037){ref-type="ref"}

2.3. Immunomodulation {#jcmm13564-sec-0012}
---------------------

Studies showed that PCP could enhance host immune function and activate the immune response.[26](#jcmm13564-bib-0026){ref-type="ref"}, [36](#jcmm13564-bib-0036){ref-type="ref"}, [40](#jcmm13564-bib-0040){ref-type="ref"}, [41](#jcmm13564-bib-0041){ref-type="ref"}, [42](#jcmm13564-bib-0042){ref-type="ref"}, [43](#jcmm13564-bib-0043){ref-type="ref"}, [44](#jcmm13564-bib-0044){ref-type="ref"}, [45](#jcmm13564-bib-0045){ref-type="ref"}, [46](#jcmm13564-bib-0046){ref-type="ref"}, [47](#jcmm13564-bib-0047){ref-type="ref"} It is reported that PCPs could modulate their specific immune response via the activation of T cells.[40](#jcmm13564-bib-0040){ref-type="ref"} Pachymaran strongly enhances the generation of alloreactive cytotoxic T lymphocytes in vivo.[41](#jcmm13564-bib-0041){ref-type="ref"} Generally speaking, the strength of the immune function can be judged through three aspects: the capability of macrophage\'s phagocytosis, the cellular immune function by detecting the index of immune organs[42](#jcmm13564-bib-0042){ref-type="ref"}, [43](#jcmm13564-bib-0043){ref-type="ref"} and the humoural immunity function by measuring the production of antibodies and serum haemolysins. As shown in Table [5](#jcmm13564-tbl-0005){ref-type="table"}C,D, Zhang et al and Xu et al found that the capability of macrophage\'s phagocytosis, thymus index and spleen index have significantly improved by PCP.[26](#jcmm13564-bib-0026){ref-type="ref"}, [42](#jcmm13564-bib-0042){ref-type="ref"} Zhang et al and Peng et al reported that the levels of IgA, IgG and IgM in serum are increased and the levels of IFN‐γ and IL‐4 are also enhanced by PCPs.[46](#jcmm13564-bib-0046){ref-type="ref"}, [47](#jcmm13564-bib-0047){ref-type="ref"}, [48](#jcmm13564-bib-0048){ref-type="ref"}

2.4. Antioxidation {#jcmm13564-sec-0013}
------------------

Free radicals refer to the dissociative molecules, atoms or ions with unpaired electron that reacting rapidly with other substances. Under certain range, free radicals can help to eliminate microorganisms intruding into body or abnormal cells. However, if free radicals are excessively produced, they would attack the normal cells and tissues. Therefore, human body constantly produces and removes free radicals to maintain a dynamic balance. Studies showed that PCP has antioxidant activity by scavenging free radicals. As shown in Table [6](#jcmm13564-tbl-0006){ref-type="table"},[49](#jcmm13564-bib-0049){ref-type="ref"}, [50](#jcmm13564-bib-0050){ref-type="ref"}, [51](#jcmm13564-bib-0051){ref-type="ref"}, [52](#jcmm13564-bib-0052){ref-type="ref"}, [53](#jcmm13564-bib-0053){ref-type="ref"} Li et al and Zhang et al found that PCP2 and FP could clear free radicals (O~2~ ^−^, ·OH and DPPH·) and the clearance rate of DPPH· could reach 93%.[51](#jcmm13564-bib-0051){ref-type="ref"}, [52](#jcmm13564-bib-0052){ref-type="ref"} Wang et al also found that carboxymethylated PCP has DPPH, O~2~ ^−^ and ·OH radical‐scavenging activity in vitro.[54](#jcmm13564-bib-0054){ref-type="ref"}, [55](#jcmm13564-bib-0055){ref-type="ref"} Superoxide dismutase (SOD) is an important antioxidant enzyme in organisms and Chen et al showed that CMP could increase the expression of SOD and reduce the amount of MAD (malondialdehyde).[53](#jcmm13564-bib-0053){ref-type="ref"}

###### 

Antioxidant effects of PCPs

  Groups           Deoxidization (abs)   Antioxidation (abs)   Clearance rate (%)   EC50 (g/L)         MDA in serum (nmol/mL)   MDA in hepar (nmol/mg·pro)   SOD activity in serum (U/mL)   SOD activity in hepar (U/mg·pro)   IC50 (mg/mL)      References
  ---------------- --------------------- --------------------- -------------------- ------------------ ------------------------ ---------------------------- ------------------------------ ---------------------------------- ----------------- -------------------------------------------
  BHT              0.912                 0.406                                                                                                                                                                                                   [49](#jcmm13564-bib-0049){ref-type="ref"}
  PCP              0.490                 0.546                                                                                                                                                                                                   
  CMP                                                                               2.5 (OH)                                                                                                                                                     [50](#jcmm13564-bib-0050){ref-type="ref"}
  Vc                                                                                0.2 (·OH)                                                                                                                                                    
  CMP                                                                               \>1.5 (O~2~ ^−^)                                                                                                                                             
  Vc                                                                                1.5 (O~2~ ^−^)                                                                                                                                               
  PCP (8 mg/mL)                                                76.7 (·OH)                                                                                                                                                                        [51](#jcmm13564-bib-0051){ref-type="ref"}
  PCP (10 mg/mL)                                               59.3 (O~2~ ^−^)                                                                                                                                                                   
  PCP (5 mg/mL)                                                93.4 (DPPH)                                                                                                                                                                       
  FP (4 mg/mL)                                                 58.72 (·OH)          2.5(·OH)                                                                                                                                                     [52](#jcmm13564-bib-0052){ref-type="ref"}
  FP (4 mg/mL)                                                 39.7 (DPPH·)                                                                                                                                                                      
  CMP                                                                                                                                                                                                                          2.57 (O~2~ ^−^)   [53](#jcmm13564-bib-0053){ref-type="ref"}
                                                                                                                                                                                            7.66 (·OH)                                           
                                                                                                                                                                                            4.56 (H~2~O~2~)                                      
  NS                                                                                                   12.38                    40.54                        9.12                           187.56                                               
  CMP‐L                                                                                                12.05                    31.75                        9.87                           190.52                                               
  CMP‐M                                                                                                11.52                    28.53                        10.25                          204.78                                               
  CMP‐H                                                                                                8.74                     24.62                        12.67                          224.63                                               
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2.5. Other pharmacological activities {#jcmm13564-sec-0014}
-------------------------------------

PCPs have other biological effects, such as anti‐inflammatory,[56](#jcmm13564-bib-0056){ref-type="ref"} anti‐ageing,[57](#jcmm13564-bib-0057){ref-type="ref"} antihepatitis,[58](#jcmm13564-bib-0058){ref-type="ref"}, [59](#jcmm13564-bib-0059){ref-type="ref"} antidiabetic,[60](#jcmm13564-bib-0060){ref-type="ref"} anti‐ALL (acute lymphoblastic leukaemia),[61](#jcmm13564-bib-0061){ref-type="ref"} anti‐nephritic[62](#jcmm13564-bib-0062){ref-type="ref"} and antihypertensive effects.[63](#jcmm13564-bib-0063){ref-type="ref"} These pharmacological activities are summarized in Table [7](#jcmm13564-tbl-0007){ref-type="table"}A,B. Hou et al observed that PCP reduces the size of granuloma.[56](#jcmm13564-bib-0056){ref-type="ref"} As an anti‐ageing reagent, PCPs enhance the activities of both T‐SOD and Cu‐SOD and reduce MAD and MAO (monoamine oxidase) activities.[57](#jcmm13564-bib-0057){ref-type="ref"} To understand the antihepatitis effects of CMP, it is found that CMP reduces the expression of HBsAg and HBeAg in a concentration‐dependent manner.[58](#jcmm13564-bib-0058){ref-type="ref"} Zheng et al reported that PCP could reduce blood glucose level and increase the weight of mice in a diabetic mouse model.[60](#jcmm13564-bib-0060){ref-type="ref"} Meanwhile, CMP significantly improves the survival rates of mice suffering acute lymphoblastic leukaemia or ALL.[61](#jcmm13564-bib-0061){ref-type="ref"}

###### 

\(A\) Other pharmacological effects of PCPs: anti‐inflammatory, anti‐ageing and antihepatitis effects (B) Other pharmacological effects of PCPs: antidiabetic and anti‐acute lymphoblastic leukaemia effects

  Other effects                                     Groups                   Swelling degree (mg)   Granuloma (mg/10 g)   T‐SOD   Cu‐SOD   MDA   MAO    Death time of swimming (min)   Inhibition of HBsAg (%)   Inhibition of HBeAg (%)   Inhibition of Anti‐HBc   Inhibition of SGPT                          References
  ------------------------------------------------- ------------------------ ---------------------- --------------------- ------- -------- ----- ------ ------------------------------ ------------------------- ------------------------- ------------------------ ------------------------------------------- -------------------------------------------
  \(A\)                                                                                                                                                                                                                                                                                                         
  Anti‐inflammatory effects                         NS                       6.2                    47                                                                                                                                                                                                          [56](#jcmm13564-bib-0056){ref-type="ref"}
  DXM                                               3.2                      13                                                                                                                                                                                                                                 
  PCP‐L                                             3.6                      36                                                                                                                                                                                                                                 
  PCP‐M                                             7.4                      40                                                                                                                                                                                                                                 
  PCP‐H                                             8.5                      38                                                                                                                                                                                                                                 
  Anti‐ageing effects                               Double distilled water                                                108     46       7.1   16     2.48                                                                                                                                                    [57](#jcmm13564-bib-0057){ref-type="ref"}
  PCP‐L                                                                                             114                   54      6.7      19    3.68                                                                                                                                                           
  PCP‐M                                                                                             125                   60      6.5      16    4.93                                                                                                                                                           
  PCP‐H                                                                                             127                   62      6.3      13    6.15                                                                                                                                                           
  Antihepatitis effects                             ACV‐L                                                                                                                              23.5                      18.7                                                                                           [58](#jcmm13564-bib-0058){ref-type="ref"}
  ACV‐M                                                                                                                                                 50.7                           30.5                                                                                                                     
  ACV‐H                                                                                                                                                 61.4                           51.1                                                                                                                     
  CMP (1.5 g/L)                                                                                                                                         37.4                           30.4                                                                                                                     
  CMP (3.0 g/L)                                                                                                                                         46.3                           47.0                                                                                                                     
  CMP (6.0 g/L)                                                                                                                                         56.2                           58.5                                                                                                                     
  CMP (12.0 g/L)                                                                                                                                        71.8                           65.3                                                                                                                     
  Traditional Chinese medicine                                                                                                                          22.3                           36.3                      28.5                      32.3                     [59](#jcmm13564-bib-0059){ref-type="ref"}   
  CMP‐induced IFN‐α+ Traditional Chinese medicine                                                                                                       52.1                           95.4                      75                        80                                                                   

  Other effects          Groups            The weight of mice after 30 days (g)   Blood glucose of mice after 30 days (mg %)   Life prolonging rates (%)   Expression rates of Bcl‐2   References
  ---------------------- ----------------- -------------------------------------- -------------------------------------------- --------------------------- --------------------------- -------------------------------------------
  \(B\)                                                                                                                                                                                
  Antidiabetic effects   Distilled water   163.8                                  19.72                                                                                                [60](#jcmm13564-bib-0060){ref-type="ref"}
  Melbine                168.64            11.35                                                                                                                                       
  PCP‐L                  201.32            15.4                                                                                                                                        
  PCP‐H                  213.58            15.16                                                                                                                                       
  Effects on ALL mice    NS                                                                                                    0                           18.4                        [61](#jcmm13564-bib-0061){ref-type="ref"}
  CTX                                                                             58.84                                        40.5                                                    
  KSC                                                                             25.83                                        68.9                                                    
  CMP                                                                             35.88                                        36.3                                                    
  KSC+CMP                                                                         43.97                                        40.1                                                    
  KSC+CMP+CTX                                                                     79.68                                        26.7                                                    

IFN‐α was obtained from human peripheral blood lymphocytes treated with CMP.
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3. CLINICAL EFFICACY OF PCP {#jcmm13564-sec-0015}
===========================

Seven clinical studies on PCPs were found through literature search.[59](#jcmm13564-bib-0059){ref-type="ref"}, [64](#jcmm13564-bib-0064){ref-type="ref"}, [65](#jcmm13564-bib-0065){ref-type="ref"}, [66](#jcmm13564-bib-0066){ref-type="ref"}, [67](#jcmm13564-bib-0067){ref-type="ref"}, [68](#jcmm13564-bib-0068){ref-type="ref"} The clinical data are summarized in Table [8](#jcmm13564-tbl-0008){ref-type="table"}. Most of studies are related to the antitumour effects of CMP where these studies use IL‐2 or IFN‐α obtained from human peripheral blood lymphocytes induced by CMP in combination with chemotherapy or radiotherapy. Sheng et al reported that the total effective rate could reach 97% when CMP‐induced IL‐2 is combined with chemotherapy during cancer treatment compared to that of 27% by chemotherapy alone.[65](#jcmm13564-bib-0065){ref-type="ref"} The effectiveness is defined as improving the symptoms of the disease by increasing appetite, elevating the levels of cAMP in blood circulation, regulating the ratio of cAMP/cGMP, protecting and restoring damaged liver and reducing the side effects of chemotherapy.[66](#jcmm13564-bib-0066){ref-type="ref"} In treating epidemic haemorrhagic fever, cure rate could reach 100% when CMP‐induced IFN‐α is combined with normal therapy compared to that of 63% with normal therapy alone.[64](#jcmm13564-bib-0064){ref-type="ref"} Chen et al also found that the total effective rate could reach 90% during hepatitis treatment.[66](#jcmm13564-bib-0066){ref-type="ref"} The changes of immune functions are measured with Et (total erythrocyte rosettle test), Ea (active erythrocyte rosettle test) and LCT (lymphocytes transformation) during PCP treatment. These values are significantly increased compared to the control groups when PCP is combined with chemotherapy[67](#jcmm13564-bib-0067){ref-type="ref"} (Table [8](#jcmm13564-tbl-0008){ref-type="table"}).

###### 

PCP‐related clinical studies

  Diseases types                                   Cases                                                          Groups                                      Total effective rate (%)   NK cell activity (%)   Cure rate (%)   Et (%)   LCT (%)   Ea (%)                                      References
  ------------------------------------------------ -------------------------------------------------------------- ------------------------------------------- -------------------------- ---------------------- --------------- -------- --------- ------------------------------------------- -------------------------------------------
  Antitumour effects                               71                                                             Mitomycin/cis‐platinum/pharmorubicin/5‐Fu   25.9                                                                                                                             [63](#jcmm13564-bib-0063){ref-type="ref"}
                                                   Mitomycin/cis‐platinum/pharmorubicin/5‐Fu + CMP‐induced IL‐2   86.7                                                                                                                                                                         
  44                                               Mitomycin/cis‐platinum/doxorubicin/5‐Fu + CMP‐induced IL‐2     86.4                                                                                                                             [65](#jcmm13564-bib-0065){ref-type="ref"}   
  37                                               ^60^Co radiotherapy + CMP‐induced IL‐2                         97.3                                                                                                                                                                         
  77                                               ^60^Co radiotherapy + CMP‐induced IFN‐α                        97.4                                                                                                                             [59](#jcmm13564-bib-0059){ref-type="ref"}   
  25                                               Mitomycin/cis‐platinum/pharmorubicin/5‐Fu+ CMP‐induced IFN‐α   92                                                                                                                                                                           
  Effects on epidemic haemorrhagic fever           128                                                            Balanced salt solution                      60                                                68.7                                                                           [64](#jcmm13564-bib-0064){ref-type="ref"}
  Balanced salt solution+ IFN‐α                    63                                                                                                         100                                                                                                                              
  Antihepatitis effects                            35                                                             CMP                                         88.57                                             54.28                                                                          [66](#jcmm13564-bib-0066){ref-type="ref"}
  30                                               CMP                                                            90                                                                     36.67                                                                                                 
  30                                               CMP                                                            90                                                                     30                                                                                                    
  60                                               Mitomycin/cis‐platinum/pharmorubicin/5‐Fu                                                                                                                    30.7            38.7     20.5      [67](#jcmm13564-bib-0067){ref-type="ref"}   
  Mitomycin/cis‐platinum/pharmorubicin/5‐Fu+ PCP                                                                                                                                         38.5                   50.4            27.5                                                           
  50                                               Control                                                                                                                                                      47.4            46.2     23.3      [68](#jcmm13564-bib-0068){ref-type="ref"}   
  PCP                                                                                                                                                                                    49.2                   55.4            33.3                                                           

IL‐2 and IFN‐α were obtained from human peripheral blood lymphocytes treated with CMP.

John Wiley & Sons, Ltd

4. TOXICITY {#jcmm13564-sec-0016}
===========

CMP has very low toxicity. It is reported by Chen et al[69](#jcmm13564-bib-0069){ref-type="ref"} that the mice moves freely, no abnormal reaction is observed when CMP is used during standard acute toxicity test. No teratogenic effects are detected on rats when CMP is used in the teratogenic tests. No toxic reaction is witnessed when the dogs are continuously injected by intravenous injection reported by Ye et al[70](#jcmm13564-bib-0070){ref-type="ref"} They further demonstrated that blood pressure, heart rate, electrocardiogram and breathy of dogs are not affected after intravenously injecting either 400 mg/kg or 800 mg/kg CMP. In consistent, Chai et al[71](#jcmm13564-bib-0071){ref-type="ref"} reported that CMP has no adverse effects on mice as well. Wang et al showed that CMP could enhance the tumour inhibition rate of 5‐FU and decrease the liver injuries simultaneously caused by 5‐FU in CT26 tumour‐bearing mice.[72](#jcmm13564-bib-0072){ref-type="ref"}

5. FUTURE PERSPECTIVES {#jcmm13564-sec-0017}
======================

In this article, the structure, pharmacological effects, clinical efficacy, immunobalancing molecular mechanism and toxicity of PCPs are summarized in Figures [1](#jcmm13564-fig-0001){ref-type="fig"}, [2](#jcmm13564-fig-0002){ref-type="fig"}, [3](#jcmm13564-fig-0003){ref-type="fig"}, [4](#jcmm13564-fig-0004){ref-type="fig"}, [5](#jcmm13564-fig-0005){ref-type="fig"} and Tables [1](#jcmm13564-tbl-0001){ref-type="table"}, [2](#jcmm13564-tbl-0002){ref-type="table"}, [3](#jcmm13564-tbl-0003){ref-type="table"}, [4](#jcmm13564-tbl-0004){ref-type="table"}, [5](#jcmm13564-tbl-0005){ref-type="table"}, [6](#jcmm13564-tbl-0006){ref-type="table"}, [7](#jcmm13564-tbl-0007){ref-type="table"}, [8](#jcmm13564-tbl-0008){ref-type="table"}. The broad spectrum of therapeutic properties, relatively low toxicity and low costs make PCPs attractive immune therapeutics for treating not only different types of cancers but also hepatitis B and other diseases.

Both advantages and disadvantages of PCPs as drugs rely on their complicated polysaccharide structure‐dependent immune regulatory functions. Thus, there is a great need for clarifying the active ingredients in PCPs besides β‐glucan/pachymaran and their molecular targets responsible for their drug effects. In addition, how to standardize the quality of PCPs, especially the degree of chemical modifications of pachymaran derivatives and how to perform reliable pharmacokinetic studies of PCPs are some of important issues to be solved in near future to make use of PCPs for treating patients with cancer worldwide.
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